<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02245451</url>
  </required_header>
  <id_info>
    <org_study_id>1182.26</org_study_id>
    <nct_id>NCT02245451</nct_id>
  </id_info>
  <brief_title>Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers</brief_title>
  <official_title>A Single-centre, Open-label Study of Multiple Doses of Tipranavir 500 mg and Ritonavir 200 mg (Twice Daily) on the Pharmacokinetic Characteristics of Methadone Administered as a Single Dose in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterise the effects of tipranavir 500 mg and
      ritonavir 200 mg (TPV/r; given twice daily) at steady-state on the pharmacokinetics of
      methadone administered as a single dose in healthy adult volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve for 0 to 24 hours (AUC0-24h) of methadone</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration at 6 hours (C6h) of methadone</measure>
    <time_frame>6 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve for 0 to 12 hours (AUC0-12h) of tipranavir and ritonavir</measure>
    <time_frame>up to 12 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>concentration at 12 hours (C12h) of tipranavir and ritonavir</measure>
    <time_frame>12 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>mean residence time (MRT)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent terminal half-life (tÂ½)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to maximum concentration (Tmax)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>oral clearance (CL/F)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent volume of distribution during the terminal elimination phase divided by the bioavailability factor (Vz/F)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>Up to day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>Up to day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>Up to day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to day 17 after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>TPV/r with methadone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tipranavir</intervention_name>
    <arm_group_label>TPV/r with methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <arm_group_label>TPV/r with methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methadone</intervention_name>
    <arm_group_label>TPV/r with methadone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female healthy volunteers aged at least 18 to 60 years.

          -  Clinically normal medical history.

          -  Clinically normal findings on physical examination.

          -  Clinically normal laboratory values.

          -  A Body Mass Index &gt;18.5 and &lt;30 kg/m2.

          -  Able to swallow large capsules without difficulty.

          -  Capable of comprehending and communicating effectively with the investigator and staff
             and of providing written informed consent in accordance with ethics committee and
             regulatory guidelines.

          -  Willing to stay in the study centre for the duration of the study.

          -  Willing to abstain from ingesting substances during the study which may alter plasma
             study drug levels by interaction with the cytochrome P450 system.

          -  Willing to abstain from alcohol for 48 hours prior to Visit 1 and for the duration of
             the study. In addition, Cabernet Sauvignon must not have been ingested within 15 days
             prior to Visit 1.

          -  Willing to abstain from ingesting grapefruit and grapefruit juice for 15 days before
             Visit 1 and for the duration of the study.

          -  Willing to abstain from ingesting Seville oranges, strawberries or strawberry extract,
             garlic supplements, St. John's Wort, Milk Thistle, or methylxanthine-containing drinks
             or food (coffee, tea, cola, energy drinks, chocolate, etc) for 72 hours before the
             pharmacokinetic sampling days.

          -  Willing to abstain from use of tobacco products for the duration of the study.

          -  Urine drug screen negative for illegal non-prescription drugs.

          -  Negative HIV serology.

          -  Negative for Hepatitis B surface antigen and Hepatitis C

        Exclusion Criteria:

          -  Any clinically significant disease. (A significant disease was defined as a disease
             which in the opinion of the investigator may either have put the subject at risk
             because of participation in the study or a disease which may have influenced the
             results of the study or the subject's ability to participate in the study.)

          -  Clinically significant abnormal baseline haematology, blood chemistry or urinalysis
             findings.

          -  Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), cholesterol,
             triglyceride or glucose greater than the upper limit of normal at Visit 1.

          -  Treatment with prohibited medications in the thirty days before the study or during
             the study or ingestion of drugs of abuse.

          -  Treatment with any investigational drug within 90 days of the first dose of study
             medication.

          -  Inability to adhere to the requirements of the protocol (including active substance
             abuse) as assessed by the investigator.

          -  Prior tipranavir use.

          -  Ingestion of any known enzyme altering drug (such as phenothiazines, cimetidine,
             barbiturates, ketoconazole, fluconazole, clarithromycin, rifampin, steroids, and
             herbal medications) for thirty days prior to Visit 1.

          -  Ingestion of grapefruit, grapefruit juice, and Cabernet Sauvignon within fifteen days
             prior to Visit 1.

          -  Ingestion of Seville oranges, strawberries or strawberry extract, garlic supplements,
             St. John's Wort, Milk Thistle, or methylxanthine-containing drinks or food (coffee,
             tea, cola, energy drinks, chocolate, etc) within 72 hours of pharmacokinetics sampling
             days.

          -  Treatment with prescription medicines within thirty days prior to Visit 1.

          -  History of gastrointestinal, hepatic, or renal disorders within 60 days prior to Visit
             1.

          -  Any history of alcohol or drug abuse.

          -  Current use of cigarettes defined as greater than 10 cigarettes per day or
             rolling/pipe tobacco equivalent.

          -  Blood or plasma donations within 90 days prior to Visit 1

          -  Subjects with a seated systolic blood pressure either &lt;100 mm Hg or &gt;150 mm Hg;
             resting heart rate either &lt;50 beats/min or &gt;100 beats/min.

          -  Subjects with a history of any illness or allergy that, in the opinion of the
             investigator, might have confounded the results of the study or posed additional risk
             in administering tipranavir, ritonavir or methadone to the subject.

          -  Subjects who had an acute illness within two weeks prior to Visit 1.

          -  Subjects who were currently taking any over-the-counter drug within fourteen days
             prior to Visit 1 or who were currently taking any prescription drug.

          -  Hypersensitivity to tipranavir, ritonavir, or methadone.

          -  Female subjects who are of reproductive potential and who were pregnant,
             breastfeeding, had a positive serum B-HCG at Visit 1 or 2, had not been using a
             barrier contraceptive method for at least three months prior to Study Day 1 or were
             not willing to use a reliable method of double-barrier contraception (such as
             diaphragm with spermicidal cream/jelly or condoms with spermicidal foam) during the
             study and for thirty days after completion or termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 18, 2014</study_first_submitted>
  <study_first_submitted_qc>September 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2014</study_first_posted>
  <last_update_submitted>September 18, 2014</last_update_submitted>
  <last_update_submitted_qc>September 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Tipranavir</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

